ASX ANNOUNCEMENT **19 January 2026**

Special Meeting of Stockholders and Preliminary Proxy Update

Sunnyvale, California; 19 January 2026: EBR Systems, Inc. (ASX: **"EBR"**, **"EBR Systems"**, or the **"Company"**), developer of the world's only wireless cardiac pacing device for heart failure, announces it will hold a Special Meeting of Stockholders (**Special Meeting**) as a virtual meeting on Thursday, 12 March 2026 at 9:00am AEDT (Wednesday, 11 March 2026 at 3:00pm U.S. PDT).

The Company has filed its preliminary proxy statement for the Special Meeting (**Notice of Meeting**) with the United States Securities and Exchange Commission (**SEC**) for review. SEC rules require that the Notice of Meeting be publicly available during its review period, and it can be accessed **here**. It has also been provided to the Australian Securities Exchange (**ASX**) for review. The preliminary Notice of Meeting is subject to change prior to final release and dispatch to securityholders, following the completion of the SEC-mandated review period and reviews by the SEC and ASX.

The Notice of Meeting includes agenda items relating to:

- A proposed amendment to the Company's charter to implement a share consolidation (reverse stock split) within a range of 1:5 and 1:20, with the final ratio to be determined by the Board. The CDIs will not be consolidated as part of the share consolidation but rather the transmutation ratio of CDIs to shares will change from 1-to-1 to the ratio at which the consolidation is effected; and
- the ratification and approval of a prior issuance of securities pursuant to an institutional placement completed by the Company on 27 May 2025 (U.S. PDT) / 28 May 2025 (AEST).

There will be no change to the total amount of authorised shares in the Company's charter as a result of the consolidation, which will remain 600,000,000 authorised shares of Common Stock and 10,000,000 authorised shares of Preferred Stock. Additionally, there will be no change to the number of issued CDIs or to the price of CDIs as a result of the common stock share consolidation.

Communication to securityholders of the Company (both holders of common stock and CHESS Depositary Interests) in relation to the Notice of Meeting will be dispatched on or around 27 January 2026 (U.S. PST) / 28 January 2026 (AEDT). The Notice of Meeting will also be available on the ASX Market Announcements Platform and the Company's website (www.ebrsystemsinc.com). The Notice of Meeting will provide details on how to view and listen to the meeting presentations, vote online and submit questions in real-time.

Investor webinar:
In advance of the Special Meeting, EBR's senior management team will host an investor webinar to outline the strategic rationale for the proposed share consolidation. The webinar will be held on **Wednesday, 21 January 2026 at 11:00am AEDT** (Tuesday, 20 January 2026 at 4:00pm PST). Investors can register for the webinar via the following link:

https://us02web.zoom.us/webinar/register/WN_N09MowjJRLaCir7OPxm8sQ

This announcement has been authorised for release by the Routine Disclosure Committee, a Committee of the Board.

For more information, please contact:

Company
Andrew Shute
Chief Corporate Development Officer
P: +44 7730 691421
E: info@ebrsystemsinc.com

Investor Relations
Gabriella Hold
The Capital Network
P: +61 2 8999 3699
E: gaby@thecapitalnetwork.com.au

Julia Maguire
The Capital Network
P: +61 2 8999 3699
E: julia@thecapitalnetwork.com.au

About EBR Systems

Silicon Valley-based EBR Systems (ASX: EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

EBR Systems' WiSE Technology

EBR Systems' WiSE technology is the world's only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart's left ventricle. This has long been a goal of cardiac pacing companies since internal stimulation of the left ventricle is thought to be a potentially superior, more anatomically correct pacing location. WiSE technology enables cardiac pacing of the left ventricle with a novel cardiac implant that is roughly the size of a large grain of rice. The need for a pacing wire on the outside of the heart's left ventricle – and the attendant problems – are potentially eliminated. WiSE is an investigational device and is not currently available for sale in the US.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company's control, subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory applications and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. EBR does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. EBR may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Foreign Ownership Restriction

EBR's CHESS Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of EBR's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act, or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.